High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Isoniazid
  • Pyrazinamide
  • Rifampin
  • Tuberculosis*
  • Tuberculosis, Multidrug-Resistant*

Substances

  • Pyrazinamide
  • Isoniazid
  • Rifampin